OncoSec Announces Publication of Positive TAVO™ Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncology

Mar 17, 2020 8:30am EDT

OncoSec Receives $850,000 from The Australian Research and Development (R&D) Tax Incentive Program for TAVO™ R&D Work in 2019

Mar 11, 2020 8:30am EDT

OncoSec Announces that the Class Action and Related Litigation Brought by Alpha Holdings Have Been Dismissed by Nevada State Court with Prejudice

Mar 09, 2020 8:30am EDT

OncoSec Strengthens its Board of Directors with Three New Appointments

Feb 11, 2020 8:30am EST

OncoSec Announces Closing of the CGP/Sirtex Transaction

Feb 10, 2020 8:30am EST

OncoSec Announces that Shareholders Have Approved CGP/Sirtex Transaction

Feb 07, 2020 10:53am EST

OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders

Feb 07, 2020 8:00am EST

Clinical Cancer Research highlights OncoSec’s Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue

Feb 04, 2020 8:30am EST

OncoSec’s Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting

Feb 03, 2020 8:46am EST

OncoSec Urges Shareholders to Focus on the Critical Benefits of CGP/Sirtex Transaction

Jan 31, 2020 8:30am EST